Research Papers:
Metabonomics studies on serum and urine of patients with breast cancer using 1H-NMR spectroscopy
Metrics: PDF 1440 views | HTML 2096 views | ?
Abstract
Jianping Zhou1, Yanxia Wang1, Xinli Zhang1
1Radiation Immunity Test Center, Shaanxi Provincial People’s Hospital, Xi'an, China
Correspondence to:
Xinli Zhang, email: [email protected]
Keywords: breast cancer, 1H-NMR, metabonomics, serum, urine
Received: February 06, 2017 Accepted: March 03, 2017 Published: March 15, 2017
ABSTRACT
The aim of this study was to describe a metabolomic study of breast cancer using 1H-NMR combined with bioinformatics analysis. 1H-NMR spectroscopy combined with multi-variate pattern recognition analysis was used to cluster the groups (serum and urine samples from breast cancer patients and healthy controls) and establish a breast-cancer-specific metabolites phenotype. Orthogonalpartial least-squares discriminant analysis (OPLS-DA) was capable of distinguishing serum and urine samples from breast cancer patients and healthy controls and establishing a breast-cancer-specific metabolite profile. A total of 9 metabolites in serum concentration and 3 metabolites in urine concentration differed significantly between breast cancer patients and healthy controls. Serum samples from breast cancer patients were characterized by decreased concentrations of choline, glucose, histidine, valine, lysine, acetate, tyrosine and glutamic, accompanied by increased concentrations of lipid relative to healthy controls. In urine samples, the level of phenylacetylglycine and guanidoacetate was significantly lower, while the level of citrate was significantly higher in breast cancer patients relative to healthy controls. In conclusion, this study reveals the metabolic profile of serum and urine from breast cancer patients. NMR-based metabolomics has the potential to be developed into a novel clinical tool for diagnosis or therapeutic monitoring for breast cancer. However, because of limitations of methods and technique, further research and verification is needed.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16210